Biopsy specimens indicating a METAVIR score of F0–F3 within 3 years of screening, or a score of F4 at any previous time, were acceptable. In total, 68% of patients had a biopsy within a year of screening. Subjects with bridging fibrosis (F3) or cirrhosis
(F4) were eligible Dabrafenib cell line if they had an ultrasound performed within 6 months before screening (or between the screening and baseline visit) with no findings suspicious for hepatocellular carcinoma. Patients with hepatic decompensation; non–HCV-related liver disease; co-infection with human immunodeficiency virus, hepatitis B virus, or non–genotype 1 HCV; defined laboratory abnormalities (Supplementary Materials and Methods section); any other active disease; or who were either pregnant or planning pregnancy were excluded. This was a randomized, multicenter, double-blind,
parallel-group, placebo-controlled, PLX4032 supplier phase 3 clinical trial (NCT01281839), conducted between January 2011 and January 2013. Institutional review boards of all participating institutions approved the study and written informed consent was obtained from all participants according to local regulations. All authors had access to the study data, critically reviewed the manuscript at each draft, and approved the final draft for submission. After stratification by HCV 1 subtype (1a, 1b, and other) and IL28B genotype (rs12979860; CC, CT, or TT), participants were randomized centrally in a 2:1 ratio to receive either simeprevir (150 mg once daily) plus PegIFNα-2a/RBV (180 μg/wk and 1000 or 1200 mg/day depending on body weight, respectively) (PR) for 12 weeks followed by RGT with PR alone for 12 or 36 weeks, or placebo with PR for 12 weeks followed by PR alone for 36 weeks ( Supplementary Figure 1). Patients, study personnel, and the Palbociclib sponsor were blinded to the treatment groups. According to RGT criteria, PR therapy was completed at week 24 in simeprevir-treated patients with HCV-RNA levels less than 25 IU/mL at week 4 and undetectable levels
at week 12. For patients not meeting these criteria and all patients in the placebo group, treatment with PR was continued until week 48. Patients in both groups were followed-up for 72 weeks after treatment initiation. According to virologic stopping rules, simeprevir/placebo was discontinued if HCV-RNA level was greater than 1000 IU/mL at week 4. PR also was discontinued if the reduction in HCV RNA compared with baseline was less than 2 log10 IU/mL at week 12, or if HCV RNA was 25 IU/mL or greater at week 24 or 36. Investigators were formally blinded to HCV-RNA data until week 48 and to treatment group until week 72. An external HCV-RNA monitor (who was unblinded to treatment and to HCV-RNA measurements results) informed the investigator if a virologic stopping rule or the RGT criteria were met. Plasma HCV RNA was determined using the Roche COBAS TaqMan HCV/HPS assay version 2.